ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy - Oncology Today with Dr Neil Love

Om avsnittet

Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer.

CME information and select publications here.

ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

Om avsnittet

Fler avsnitt

Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies

Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal

HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon

Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo

Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network